Chinese biopharmaceutical company RemeGen Co., Ltd. (SHA:688331, HKG:09995) announced on Friday that it has received clearance from the United States Food and Drug Administration to initiate Phase II clinical trials for its bispecific antibody RC148.
RC148 is a novel bispecific antibody designed for the treatment of multiple advanced malignant solid tumours targeting both PD-1 and VEGF. It was developed using RemeGen's proprietary bispecific antibody technology platform.
Clinical trials for RC148, both as a monotherapy and in combination treatments, are currently ongoing in China.
FDA approval to proceed with US trials represents a major milestone in RC148's global clinical development strategy.
FDA lifts pause on Valneva's chikungunya vaccine IXCHIQ for elderly, updates prescribing information
Jazz Pharmaceuticals' Modeyso approved by US FDA for H3 K27M-mutant diffuse midline glioma treatment
Freenome and Exact Sciences agree licensing deal for CRC blood test
Intas Pharmaceuticals and Accord BioPharma acquire UDENYCA (pegfilgrastim-cbqv)
FDA approves Teva's AJOVY for paediatric episodic migraine prevention
Galapagos receives FDA RMAT designation for CAR-T therapy in mantle cell lymphoma
Novo Nordisk expands legal action over compounded 'semaglutide'
US FDA approves Innovent's IND application for IBI3032 oral GLP-1R agonist
Mabwell's 7MW4911 IND application accepted by regulators in China and US
Novartis' new Leqvio (inclisiran) indication receives FDA approval
Novo Nordisk's Alhemo haemophilia treatment receives expanded US FDA approval
Zenara Pharma's Sertraline Hydrochloride Capsules generic receives US FDA approval